Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Wanxiang Pharmaceutical is a comprehensive pharmaceutical enterprise based in China, focused on the research, development, and manufacturing of chemical drugs and active pharmaceutical ingredients (APIs). The company maintains a strong presence in the generic drug market, producing a wide range of oral solid dosages and injectable formulations. Its core therapeutic focus includes cardiovascular diseases, anti-infectives, and gastrointestinal disorders. With multiple GMP-certified facilities, the company serves as both a domestic supplier and a contract manufacturer for global markets. It is a subsidiary of the Wanxiang Group, leveraging significant industrial resources to maintain high-volume production capabilities. The company's product portfolio includes essential medicines such as amlodipine and various macrolide antibiotics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Wanxiang Pharmaceutical.